Short communication · 29 Nov 2025
Conference abstractPublished 14 Jun 2021
Short chain fatty Acids delay the pathogenesis of hepatitis B virus-associated hepatocellular carcinoma in an HBx transgenic mouse model
Dept. of Biology, Temple University. Philadelphia, PA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chronic infection with hepatitis B virus (HBV) is a major risk factor for hepatocellular carcinoma (HCC). The HBV encoded oncoprotein, HBx, alters host gene expression and the activity of multiple signal transduction pathways. Short chain fatty acids (SCFAs) have strong anti-inflammatory and anti-neoplastic properties, suggesting that they may block the progression of chronic liver disease (CLD) to HCC. This hypothesis was evaluated in HBx transgenic (HBxTg) mice fed SCFAs. Groups of HBxTg mice were fed with SCFAs or vehicle from 6-9 months of age and then assessed for dysplasia, and from 9-12 months of age and then assessed for HCC. Livers from 12 mo. old mice were then analyzed for changes in gene expression by mass spectrometry-based proteomics. SCFA-fed mice had significantly fewer dysplastic and HCC nodules compared to PBS fed controls at 9 and 12 months, respectively. Pathway analysis of SCFA-fed mice showed downregulation of several signaling pathways altered by HBx in human CLD and HCC, including those involved in inflammation, PI3K, EGF, and Ras. SCFA treatment decreased activity of the Ras pathway, which is constitutively activated by HBx. In vitro work showed that SCFAs reduced cell viability in HBx-transfected cell lines in a dose-dependent manner while the viability of primary human hepatocytes was unaffected. These results show for the first time that SCFAs may oppose some of the carcinogenic alterations mediated by HBx, thus indicating that SCFAs may delay the pathogenesis of HBV-associated HCC.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Hepatology and Pancreatic Science.
Short communication · 29 Nov 2025
Understanding Drug-Induced Liver and Pancreatic Toxicity
Opinion · 29 Nov 2025
Nanomedicine Enhances Hepatopancreatic Disorder Treatment
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalHepatology and Pancreatic Science
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Mark Feitelson”
